Novo Nordisk A/S (NVO) 55.24 $NVO Drug Manufacturers

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Novo Nordisk A/S (NVO) 55.24 $NVO

Drug Manufacturers Stocks on Investors' Radar -- Synergy Pharma, Novo Nordisk, Biodel, and DURECT
PR Newswire - Thu Aug 04, 7:10AM CDT
The Drug Manufacturers segment is an intensive space that is driven by demand for medicines and related health-care products. Long-term industry outlook is positive with global sales projected to reach $1.4 trillion by 2019. Stock-Callers.com takes a look at the following companies and see what investors make of them: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Biodel Inc. (NASDAQ: BIOD), and DURECT Corp. (NASDAQ: DRRX). Learn more about these stocks by downloading their comprehensive and free reports at:
SGYP: 4.27 (+0.07), NVO: 55.24 (-0.11), DRRX: 1.86 (-0.02), BIOD: 0.41 (+0.01)

Novo Nordisk Falls 2.03% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Aug 02, 2:29PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $55.86 to a high of $56.30. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $56.32 on volume of 2.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVO: 55.24 (-0.11)

Lyfebulb Partners With Novo Nordisk A/S to Support Patient-Driven Innovations for People With Diabetes
Marketwire Canada - Tue Jul 19, 7:30AM CDT
NEW YORK, NY--(Marketwired - Jul 19, 2016) - Lyfebulb, a patient-centric company that empowers patient entrepreneurs to deliver innovative products and solutions to patients living with chronic disease, announces a partnership with Novo Nordisk A/S, a global healthcare company driving change to defeat diabetes.
NVO: 55.24 (-0.11)

Novo Nordisk to Present 28 Abstracts at the World Federation of Hemophilia World Congress in Orlando
PR Newswire - Mon Jul 11, 11:00AM CDT
Novo Nordisk announced today that data from 28 abstracts will be shared at the upcoming World Federation of Hemophilia (WFH) World Congress in Orlando, FL, from July 24-28. The WFH Congress is the largest international meeting for the global bleeding disorders community.
NVO: 55.24 (-0.11)

Brenntag Specialties Inc. (BSI) Expands Pharmaceutical, Over-the-Counter (OTC), and Personal Care Product Offering with Novo Nordisk Pharmatech A/S
PRWeb - Thu Jun 16, 9:09AM CDT
Brenntag Specialties, Inc. (BSI) and Novo Nordisk Pharmatech A/S have entered into a distribution agreement for Pharmaceutical Grade Quaternary Ammonium Compounds into the Pharmaceutical, Over-the-Counter (OTC), and Personal Care Markets in the United States & Puerto Rico.
NVO: 55.24 (-0.11)

Novo Nordisk (NVO) Reports Positive Trial Results on Victoza
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 2:17PM CDT
Novo Nordisk (NVO) announced results from the LEADER trial on Victoza at the American Diabetes Association's 76th Scientific Sessions.
ABT: 44.89 (-0.06), NVO: 55.24 (-0.11), PFE: 35.27 (-0.02), BMY: 75.57 (+0.77)

Study Finds Victoza® Significantly Reduced the Risk of Heart Attack and Stroke in People with Type 2 Diabetes
CNW Group - Mon Jun 13, 7:52PM CDT
Diabetes community welcomes news that Victoza(® )reduces the risk of cardiovascular deaths by 22 per cent
NVO: 55.24 (-0.11)

Watch for Novo Nordisk to Potentially Rebound After Falling 1.01% Yesterday
Comtex SmarTrend(R) - Mon Jun 13, 4:23PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $54.20 to a high of $55.45. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $55.12 on volume of 608,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVO: 55.24 (-0.11)

Faster-acting insulin aspart showed a statistically significant reduction in HbA(1c) in type 1 diabetes and a comparable HbA(1c) reduction in type 2 diabetes versus NovoRapid® (insulin aspart)
CNW Group - Mon Jun 13, 11:40AM CDT
Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes
NVO: 55.24 (-0.11)

Novo Nordisk to Present 53 Abstracts at 76th Annual American Diabetes Association Scientific Sessions in New Orleans, LA
PR Newswire Europe - Mon Jun 06, 6:36AM CDT
BAGSVARD, Denmark, June 6, 2016 /PRNewswire/ --
NVO: 55.24 (-0.11)

Novo Nordisk (Prandin, NovoNorm, GlucoNorm, Prandimet); Daiichi Sankyo (Prandin) Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) - Research and Markets
BusinessWire - Fri Jun 03, 8:34AM CDT
Research and Markets has announced the addition of the "Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)" report to their offering.
NVO: 55.24 (-0.11)

Novo Nordisk (NVO) Reports Positive Data on Diabetes Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 8:56AM CDT
Novo Nordisk (NVO) announced positive results on its pipeline candidate, semaglutide, from the phase IIIa trial, SUSTAIN 4.
ABT: 44.89 (-0.06), JNJ: 123.89 (-0.01), NVO: 55.24 (-0.11), SNY: 40.34 (-0.61)

Sanofi's Diabetes Drug Combination Wins FDA Panel Backing
Zacks Equity Research - Zacks Investment Research - Thu May 26, 9:20AM CDT
Sanofi's (SNY) fixed-ratio combination of Lantus and Lyxumia won FDA panel backing for the treatment of type II diabetes.
MDVN: 63.70 (-0.38), NVO: 55.24 (-0.11), BMY: 75.57 (+0.77), SNY: 40.34 (-0.61)

Novo Nordisk IDegLira Recommended by FDA Advisory Committee
Zacks Equity Research - Zacks Investment Research - Wed May 25, 2:50PM CDT
Novo Nordisk (NVO) announced that the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted unanimously (16-0) in favor of the approval of IDegLira for the treatment of adults with type II diabetes.
ABT: 44.89 (-0.06), JNJ: 123.89 (-0.01), NVO: 55.24 (-0.11), SNY: 40.34 (-0.61)

IDegLira receives unanimous 16-0 vote in favor of approval from FDA Advisory Committee
PR Newswire - Tue May 24, 6:39PM CDT
Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) voted 16-0, recommending the approval of IDegLira for the treatment of adults with type 2 diabetes. IDegLira is a once-daily, single injection fixed combination of Tresiba® (insulin degludec injection 100 Units/mL) and Victoza® (liraglutide) injection for the treatment of adults with type 2 diabetes.
NVO: 55.24 (-0.11)

IDegLira receives positive 16-0 vote in favour of approval from FDA Advisory Committee
Globe Newswire - Tue May 24, 4:24PM CDT
Bagsvaerd, Denmark, 24 May 2016 - Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0, recommending the approval of IDegLira for the treatment of adults with type 2 diabetes. IDegLira is a once-daily, single injection fixed combination of insulin degludec (Tresiba(R)) and liraglutide (Victoza(R)) for the treatment of adults with type 2 diabetes.
NVO: 55.24 (-0.11)

Sanofi Diabetes Drugs Briefing Documents Raise Concerns
Arpita Dutt - Zacks Investment Research - Tue May 24, 7:07AM CDT
Sanofi's (SNY) diabetes combination drug will be coming up for review by an FDA advisory panel this week.
NVO: 55.24 (-0.11), PFE: 35.27 (-0.02), BMY: 75.57 (+0.77), SNY: 40.34 (-0.61)

US and Europe Insulin Market 2016-2020 - Key Vendors are Sanofi, Novo Nordisk & Eli Lilly
GlobeNewswire - Tue May 24, 5:20AM CDT
Research and Markets has announced the addition of the "Insulin Market in the US and Europe 2016-2020" report to their offering.
NVO: 55.24 (-0.11), LLY: 82.48 (-0.24)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Medtronic's Bold Move to Own Carotid Market Full-Scale

Updated Category News Views 64

When a giant like Medtronic makes a move, you can bet investors take notice, and this latest acquisition is no exception. They’re reaching into their deep pockets to acquire Contego Medical, a company shaking up the world of carotid artery disease treatments. It’s a tactical strike to solidify their leadership in cardiovascular solutions. Medtronic's Bet on Innovation...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 421

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 105

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 459

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Priceline's Cyber Week: A Pocket-Friendly Travel Bonanza

Updated Category News Views 88

Unpacking Priceline's Cyber Week Bonanza Alright, folks, grab your booking hats because Priceline is back with its annual Cyber Week extravaganza, aiming to give travelers a shot in the arm of savings just when inflation has everyone pinching pennies. From November 16 through December 2, Priceline rolls out the red carpet for vacation planners, offering eye-popping...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 34

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 81

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
HearUSA Expands Access with AI-Powered Hearing Aids

Updated Category News Views 61

AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 29

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 33

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering Voices: Chicago's Latina Trailblazers Unite

Updated Category News Views 156

Empowering Voices: Chicago's Latina Trailblazers Unite The Chicago History Museum is set to host a remarkable celebration of the book, Chicago Latina Trailblazers. This event recognizes the contributions of remarkable Latina leaders through compelling narratives of activism and community service. Event Overview On a significant date that marks a celebration of Latina...

Continue Reading
Mark Green to Keynote CyberScape Summit Focused on Cybersecurity

Updated Category News Views 132

Mark Green to Keynote CyberScape Summit U.S. House Homeland Security Committee Chairman Mark Green is set to showcase his insights as the keynote speaker for GovCIO Media & Research's CyberScape Summit. The event promises to be an essential gathering for those interested in advancing cybersecurity practices and policies within the government. Focus on Cybersecurity and...

Continue Reading
Brian D. Pieninck Takes Leadership Role at GuideWell

Updated Category News Views 539

Brian D. Pieninck Assumes Role as GuideWell President & CEO GuideWell Mutual Holding Corporation has recently made a significant executive decision by appointing Brian D. Pieninck as the new president and chief executive officer (CEO), effective October 1. Previously, Pieninck served as the president and CEO of CareFirst BlueCross BlueShield and was the Board Chair for...

Continue Reading
Calidi Biotherapeutics Unveils Promising CLD-401 Data at SITC

Updated Category News Views 175

Calidi Biotherapeutics Showcases CLD-401 at SITC Calidi Biotherapeutics, Inc. (NYSE: CLDI), a clinical-stage biotechnology firm, recently presented impactful new data regarding its lead therapeutic candidate CLD-401 during the Society for Immunotherapy of Cancer (SITC) Annual Meeting. This presentation highlighted the innovative capabilities of Calidi’s RedTail...

Continue Reading
Everlight Solar: Milwaukee's Top Pick for Eco Energy

Updated Category News Views 21

A High Wattage Win for Everlight Solar Milwaukee seems to have found its favorite solar squad, and it’s none other than Everlight Solar, folks. They’ve locked in the 2026 Milwaukee's Top Choice in the Solar Services Company category. Now, that’s a badge you wear with pride when it's handed out by the very community you serve. It's not every day you see a company...

Continue Reading